ADVFN US – Market Content Editor
-
Dow Jones, S&P, Nasdaq, Futures Point Higher as Tariff Exemptions Fuel Optimism on Wall Street
U.S. stock index futures indicated a positive open on Monday, hinting at a continuation of last week’s upward momentum after investors received a potentially market-friendly trade development from Washington. According to a The Wall Street Journal report, the Trump administration has been softening its tariff policy, quietly granting exemptions to some products that had previously…
-
IonQ Shares Gain After Joining Italy’s Q-Alliance Quantum Hub Initiative
IonQ (NYSE:IONQ) climbed 3.5% in premarket trading after announcing it has become a founding member of Q-Alliance, a new initiative aimed at establishing a quantum technology hub in Lombardy, Italy. The partnership supports Italy’s National Strategy for Quantum Technologies, bringing together public and private players to build a robust quantum ecosystem. The launch took place…
-
Cooper Shares Climb as Activist Jana Partners Takes Stake and Pushes for Strategic Shake-Up
Cooper Companies (NASDAQ:COO) saw its shares rise over 4% in premarket trading Monday after the Wall Street Journal reported that activist investor Jana Partners has built a stake in the company and intends to push for major strategic changes — including the potential combination of Cooper’s contact lens business with Bausch + Lomb. Jana reportedly…
-
Beyond Meat Shares Skyrocket 70% as Short Squeeze Speculation Mounts
Beyond Meat (NASDAQ:BYND) shares surged 70% in premarket trading Monday, jumping from $0.64 to $1.08, extending the strong upward momentum seen on Friday, when the stock gained 24%. The rally appears to be driven by growing speculative interest in small-cap stocks with high short interest, making Beyond Meat particularly susceptible to a short squeeze. Recent…
-
Olema Shares Sink 28% as Roche Trial Results Weigh on Breast Cancer Drug Outlook
Olema Pharmaceuticals (NASDAQ:OLMA) plunged 28% in premarket trading Monday after releasing data from an early- to mid-stage breast cancer study that was overshadowed by disappointing results from Roche. Matthew Biegler, analyst at Oppenheimer, noted that Olema’s “stellar” combination therapy data risk being eclipsed by Roche’s breast cancer trial outcome, “which missed the buy-side’s mark.” Roche’s…
-
Sable Offshore Shares Surge 15% After U.S. Energy Secretary Backs California Oil Project
Sable Offshore Corp. (NYSE:SOC) saw its stock jump 15% in premarket trading Monday after Chris Wright, the U.S. Energy Secretary, publicly voiced support for the company’s long-delayed oil project off the California coast. On Friday night, Wright took to X (formerly Twitter) to criticize state officials for stalling the approval process. “Only in California! Newsom…
-
Replimune Shares Skyrocket After FDA Accepts Resubmitted BLA for Melanoma Therapy
Replimune Group Inc (NASDAQ:REPL) surged 60% in premarket trading after the U.S. Food and Drug Administration (FDA) accepted the company’s resubmission of its Biologics License Application (BLA) for RP1, a treatment for advanced melanoma. The application seeks approval for RP1 in combination with nivolumab to treat patients with advanced melanoma who have progressed on anti-PD-1–based…
-
Investar Holding Tops Q3 Expectations as Net Interest Margin Strengthens
Investar Holding Corporation (NASDAQ:ISTR), parent company of Investar Bank, reported stronger-than-expected third-quarter earnings on Monday, boosted by improved net interest margin and steady loan growth. The Louisiana-based lender posted adjusted earnings of $0.54 per share, beating analyst forecasts of $0.46. Revenue came in at $24.14 million, ahead of the $22.5 million consensus estimate. Net income…
-
Summit Therapeutics Shares Dip After Q3 Results, Ivonescimab Strategy Moves Forward
Summit Therapeutics (NASDAQ:SMMT) saw its stock decline 3.53% in premarket trading Monday following the release of its third-quarter earnings. The company posted a non-GAAP net loss of $0.13 per share, beating analyst expectations of a $0.17 loss. Operating expenses jumped to $103.4 million on a non-GAAP basis from $39.0 million in the same period last…
-
Exelixis Shares Slide After Releasing Mixed Late-Stage Cancer Trial Data
Exelixis (NASDAQ:EXEL) saw its stock tumble 9.1% in premarket trading Monday after unveiling results from two separate late-stage studies evaluating its cancer therapies. In one update, the company reported data from a trial assessing its experimental treatment for colorectal cancer, which combines zanzalintinib with atezolizumab (marketed as Tecentriq) compared to regorafenib. After a median follow-up…